Abstract CN79
Background
The RCC treatment landscape is evolving in both the advanced and adjuvant settings. Most clinical trials prioritize progression free survival and overall survival as primary endpoints, often overlooking QoL assessments. However, integrating QoL data into trials can inform survivorship service enhancements for cancer patients and provide comprehensive information for treatment decisions. Our aim was to identify QoL endpoints and scales used in clinical trials supporting RCC drug approvals.
Methods
We searched for all drugs and indications approved for RCC in the United States (US), Canada (CAN), France (FRA), United Kingdom (UK), Spain (SPA), Italy (ITA), and Portugal (POR) from December 2005 to March 2024. We reviewed the trial publications and collected data on QoL measurement scales, as well as whether QoL was analysed as secondary or exploratory endpoint.
Results
Among the 20 identified approved indications, 14 (70%) were supported by trials that measured QoL of participants. Out of these, 8 (57%) conducted QoL analysis as a secondary endpoint, while 6 (43%) did it as an exploratory endpoint. The most frequent employed QoL scale was FKSI-DRS (64%, n=9), followed by QLQ-C30 (43%, n=6) and EQ-5D-3L (36%, n=5). Other utilised scales were EQ-5D (21%, n=3), FKSI-15 (21%, n=3), FKSI-19 (21%, n=3), EQ-VAS (14%, n=2), FACT-G (14%, n=2), FKSI-10 (7%, n=1), and FACT-G PWB (7%, n=1). Notably, out of the 14 indications with QoL data, 13 (93%) used 2 or more scales.
Conclusions
Not all the identified approved indications have published QoL data. Of those that have, roughly half have published the data as a secondary endpoint. The 10 QoL scales were used in different combinations in every study, demonstrating no consistency between trials. Without consistent and equitable measurements of QoL data across the RCC treatment landscape, how can patients be fully informed of the impact treatments may have on their QoL? In future, comparing the parameters each trial used to identify change in QoL status, and examining how many trials demonstrated sustained/improved QoL compared to Standard of Care may be useful.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
R.E. Seadon: Financial Interests, Other, Travel, Accommodations and Expenses: Ipsen. J.C. Tapia: Other, Conference Registration Fee, Travel, Accommodations and Expenses: Merck, Pfizer, Roche, MSD, EUSA Pharma UK. D. Matthews: Financial Interests, Speaker’s Bureau: Astellas, Janssen. J. Gavira-Diaz: Financial Interests, Speaker’s Bureau: Astellas, LEO Pharma; Financial Interests, Other, Travel, Accommodations and Expenses: Ipsen, BMS, Novartis, Roche. M. Santoni: Financial Interests, Research Funding: Janssen, Bristol Myers Squibb, Ipsen, MSD, Astellas, A.A.A., Bayer. M.N. Young: Financial Interests, Personal, Invited Speaker, Invited speaker to “First Thoughts in renal cell carcinoma” conference in June 2023: Eisai. R. Flippot: Financial Interests, Institutional, Invited Speaker: Ipsen, Pfizer; Financial Interests, Institutional, Advisory Board: MSD, Eisai, Astellas, Bayer, Johnson & Johnson, Merck Serono; Financial Interests, Personal, Other, Travel Expenses: Bristol Myers Squibb; Financial Interests, Institutional, Coordinating PI: Bayer. G. Anguera: Financial Interests, Speaker’s Bureau: Astellas Pharma, Ipsen, Bristol Myers Squibb, Merck/Pfizer, Leo Pharma; Financial Interests, Advisory Role: Merck; Financial Interests, Other, Travel, Accommodations, Expenses: Merck, Ipsen, Bristol Myers Squibb. R. Frazer: Financial Interests, Speaker, Consultant, Advisor: BMS, Eisai, Ewopharma, Ipsen, Merck, MSD, Novartis, Pfizer, Pierre Fabre, Recordati, Roche, Sanofi. J.P. Maroto Rey: Financial Interests, Personal, Advisory Board, Participation in Ad Boards: Bayer; Financial Interests, Personal, Advisory Board, Participation in Ad Boards: Astellas, Merck, Pfizer, MSD; Financial Interests, Personal, Invited Speaker: Janssen; Non-Financial Interests, Principal Investigator, Collaboration as PI in trials: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
CN94 - Associations between depression and quality of life after hematopoietic stem cell transplantation: A longitudinal study
Presenter: Arianna Rosich-Soteras
Session: EONS Poster Display session
Resources:
Abstract
Slides
CN95 - A novel nomogram based on inflammation biomarkers for predicting radiation cystitis in patients with local advanced cervical cancer
Presenter: Yang Sun
Session: EONS Poster Display session
Resources:
Abstract
CN96 - Patient education to support self-management and self-efficacy during immunotherapy: An integrative review
Presenter: Camilla Rothausen
Session: EONS Poster Display session
Resources:
Abstract
Slides
CN97 - Impact of a proactive telephone intervention led by the advanced practice nurse aimed at symptom control and toxicity detection on the quality of life of outpatients with lung cancer undergoing treatment
Presenter: Isabel Brao Perez
Session: EONS Poster Display session
Resources:
Abstract
Slides
CN98 - The health gains of therapeutic touch in cancer patients with pain: A literature review
Presenter: Helga Martins
Session: EONS Poster Display session
Resources:
Abstract
Slides
CN99 - Nursing management of cancer treatment related peripheral neuropathy
Presenter: Georgios Tsagkanis
Session: EONS Poster Display session
Resources:
Abstract
Slides
CN100 - Scalp cooling in breast cancer: What are women's experiences? A description and qualitative study
Presenter: Maria Rosaria Esposito
Session: EONS Poster Display session
Resources:
Abstract
Slides
CN101 - Continuous care unit for patients with cancer: Identification of the user profile and follow-up needs
Presenter: Irene Casablancas
Session: EONS Poster Display session
Resources:
Abstract
Slides
CN103 - Is my patient constipated? How do I assess? Validity and reliability study of the constipation assessment scale in cancer patients: The case of Türkiye
Presenter: Aslıhan Öztürk Çetin
Session: EONS Poster Display session
Resources:
Abstract
CN104 - Exercise interventions in the management of chemotherapy-induced peripheral neuropathy
Presenter: İlayda Eroğlu
Session: EONS Poster Display session
Resources:
Abstract
Slides